Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | GLA | P06280 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | GFER | P55789 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 3/20 | 0.53 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034430 | 0.86 | KDM4E (0.57) | KDM4EMAPTHSD17B10LMNAMEN1 | |
| SCHEMBL7708721 | 0.82 | CYP1A2 (0.63) | KDM4EMAPTHSD17B10MEN1KMT2A | |
| SCHEMBL18062744 | 0.82 | ALDH1A1 (0.58) | KDM4EMAPTHSD17B10MEN1KMT2A | |
| SCHEMBL798790 | 0.80 | SCN10A (0.69) | KDM4EHSD17B10LMNAMEN1KMT2A | |
| SCHEMBL890080 | 0.80 | CYP1A2 (0.75) | KDM4EHSD17B10LMNAKMT2AALDH1A1 | |
| SCHEMBL14267003 | 0.79 | ALPL (0.70) | KDM4EHSD17B10LMNAALDH1A1SCN10A | |
| SCHEMBL21335366 | 0.79 | KDM4E (0.57) | KDM4EMAPTHSD17B10LMNAMEN1 | |
| SCHEMBL11740622 | 0.79 | ALDH1A1 (0.61) | KDM4EMAPTHSD17B10LMNAMEN1 | |
| SCHEMBL14197238 | 0.79 | KDM4E (0.57) | KDM4EHSD17B10LMNAMEN1KMT2A | |
| SCHEMBL11932287 | 0.78 | KDM4E (0.53) | KDM4EHSD17B10LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017153952-A1 | 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030181730-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-25 | — | — | US | disclosed |
| US-20030022927-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| WO-2001051484-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | KDM4E 1828/4885MAPT 4094/4885HSD17B10 1553/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | KDM4E 1775/4885MAPT 4095/4885HSD17B10 1553/4885 |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | KDM4E 3096/4885MAPT 4305/4885HSD17B10 1398/4885 |
| US-20030022927-A1 | Novel benzimidazole derivatives | OPRL1, OPRD1, OPRM1 | KDM4E 2083/4885MAPT 4207/4885HSD17B10 1556/4885 |
| US-20030181730-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | KDM4E 1828/4885MAPT 4094/4885HSD17B10 1553/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | KDM4E 192/4885MAPT 3109/4885HSD17B10 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.